Reducing the mortality gap for people with schizophrenia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1194635

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

People with schizophrenia die >16 years earlier than the general population, mostly due to avoidable diseases such as diabetes and heart disease. This research aims to conduct clinical trials among people with schizophrenia of 1. an existing diabetes medication (metformin) to prevent initial weight gain due to antipsychotic medications and 2. a novel diabetes medication (exenatide) to help people who don’t have adequate weight loss with metformin.

Funded Activity Details

Start Date: 01-01-2020

End Date: 01-01-2025

Funding Scheme: Investigator Grants

Funding Amount: $1,231,125.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

comorbidity | diabetes mellitus | obesity | schizophrenia

Related Links